| | GLAXOSMITHKLINE EARNINGS: GSK gets good news ahead of it earnings release -- its diabetes drug Avandia was cleared from responsibility for causing heart deaths in a U.S. trial. Meanwhile the U.S. market wait for GSK's launch of Ceravix, its rival vaccine to Merck's Gardasil for cervical cancer, as investors anxiously await GSK earnings results as the company prepares for a possible period of difficulty moving ahead --- 5 products will go off patents, including its diabetes drub Avandia. Will the market embrace the release or become impatient?
| RETAILERS REPORTING: Chain stores report their January same store sales data Thursday and Margaret Brennan dissects the numbers to see if consumers still feel pinched or if the sentiment has turned. Some of the beaten down retailers have performed better than the broader market so far this year. Is the trend set to continue?
| PENDING HOME SALES: Diana Olick breaks the National Association of Realtors' pending home sales figures when they're released at 1000a ET. Do the numbers point to any signs of a bounce off a bottom? There have been new signs of life in the home builder sector. Is real recovery on the horizon?
| JOBLESS CLAIMS: Steve Liesman parses the data to for hints at where the economy stands right now. Will the jobless claims bring a brighter outlook than last week's data?
| TV GOES DIGITAL: A year from now the age of analog broadcast will come to an end -- starting Feb 17, 2009 all TV broadcasts in the U.S. will be digital, and the government is setting aside $1.5 billion in subsidies for the conversion. This is huge for the companies that make TVs, as well as the broadcasters, cable and satellite TV companies. If you can no longer get programming via antennas, satellite and cable offerings will be even more appealing! Julia Boorstin looks ahead to the future of digital TV to find the investing opportunities. Which companies win and lose? What does this mean for DISH, DTV, SNE?
|
| | Watch CNBC LIVE on your computer. Click here for more information. | | | | |
No comments:
Post a Comment